Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 7/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359052 | 1.00 | KIT (0.33) | KITBDKRB1ABCC1OPRM1OPRL1 | |
| SCHEMBL31359016 | 0.89 | S1PR3 (0.34) | KITBDKRB1OPRM1OPRL1S1PR3 | |
| SCHEMBL31359000 | 0.89 | S1PR3 (0.34) | KITBDKRB1OPRM1OPRL1S1PR3 | |
| SCHEMBL31359077 | 0.82 | ELANE (0.37) | PDPK1 | |
| SCHEMBL31358993 | 0.82 | ELANE (0.37) | PDPK1 | |
| SCHEMBL31359020 | 0.76 | GPR139 (0.39) | S1PR3PDPK1FEN1 | |
| SCHEMBL31359074 | 0.76 | GPR139 (0.39) | S1PR3PDPK1FEN1 | |
| SCHEMBL31161003 | 0.72 | PDPK1 (0.36) | KITS1PR3PDPK1 | |
| SCHEMBL31359025 | 0.72 | KDM4E (0.37) | KITS1PR3PDPK1 | |
| SCHEMBL31359019 | 0.72 | PDPK1 (0.36) | KITS1PR3PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | KIT 4669/4885BDKRB1 1015/4885ABCC1 165/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | KIT 4831/4885BDKRB1 869/4885ABCC1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.